The U.S. Patent and Trademark Office recently issued U.S. Patent No. 12,642,665 for a groundbreaking medical device titled “Talonavicular joint prosthesis”. This breakthrough technology was developed and filed by Best Step Orthopedics LLC, an innovative firm dedicated to shaping the future of lower extremity treatments. By introducing an advanced, anatomically matching implant system, the company provides an alternative to traditional, restrictive joint fusion procedures that often compromise long-term patient mobility.
The newly patented talonavicular joint prosthesis includes a navicular component designed for implantation into the navicular bone, featuring a specific base and an articulation recess, alongside a talar component configured for the talus bone with a matching bearing section. When these components are brought together during surgery, they create a unique geometry with more conformity between the components in the dorsal-plantar plane than in the medial-lateral plane. This asymmetric design preserves natural motion pathways while maintaining essential structural stability across the midfoot and hindfoot complex.
Why This Orthopedic Invention Is Highly Innovative
Historically, patients suffering from severe osteoarthritis, rheumatoid arthritis, or traumatic injuries to the talonavicular joint were forced to undergo a joint fusion, also known as arthrodesis. While fusion alleviates localized pain, it completely eliminates hindfoot motion and forces adjacent joints to absorb a significantly greater load distribution, frequently accelerating degenerative joint disease in surrounding structures. Previous attempts at total joint replacement relied on flat, non-anatomic cuts across the joint space or symmetrical disc-shaped implants. These outdated designs required the resection of an inordinate amount of healthy bone and compromised neighboring soft tissues, ultimately leading to device instability and premature mechanical failure.
The innovation of the design from Best Step Orthopedics LLC lies in its precise, multi-planar conformity that respects the native biomechanics of the foot. By maximizing conformity within the dorsal-plantar plane, the prosthesis offers robust resistance against displacement and sag under weight-bearing conditions. Concurrently, the reduced conformity in the medial-lateral plane allows for natural rotational and translational play. This enables the foot to adapt dynamically to uneven terrain, mimicking the intricate kinematics of a healthy, natural human joint while minimizing healthy bone loss during surgical preparation.
Winner of the Indiana State Patent of the Month for July 2026
Recognizing its profound impact on medical engineering and patient care, this prosthesis was awarded the prestigious title of Patent of the Month for the State of Indiana for July 2026. Given Indiana’s status as a global hub for orthopedic manufacturing and medtech development, competition for this accolade is fierce. The committee selected this patent because it elegantly solves a long-standing clinical dilemma in podiatric and orthopedic surgery: restoring multi-axial motion without sacrificing structural integrity.
The determination of July 2026 honors the technological excellence of the design and its potential to lower long-term healthcare costs by decreasing the rate of secondary revision surgeries. By expanding the horizons of motion-preserving lower extremity arthroplasty, this invention represents the highest tier of commercial and clinical ingenuity originating within the regional medtech ecosystem.
Practical Applications and Eligibility for the U.S. R&D Tax Credit
The practical development, prototyping, and clinical validation of this talonavicular joint prosthesis serve as a prime example of activities eligible for the federal Research and Development (D&R) Tax Credit in the United States. To successfully claim the credit under Internal Revenue Code Section 41, the development process must satisfy a strict four-part test. First, the project must seek to create a new or improved product or process to achieve enhanced performance, reliability, or quality. Second, it must eliminate technological uncertainty regarding the structural design, component compatibility, or multi-planar conformity of the prosthesis. Third, the company must engage in a process of experimentation, which involves evaluating alternative geometries, advanced materials like biocompatible alloys or ultra-high-molecular-weight polyethylene, and 3D modeling simulations. Finally, the research must be fundamentally grounded in the biological, physical, or engineering sciences. Qualified research expenses, including the wages of design engineers, the cost of materials consumed during prototype iterations, and specialized testing equipment fees, can be claimed to substantially reduce the company’s federal tax liability, thereby incentivizing ongoing orthopedic breakthroughs.
